Skip to main content

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting

Michaelis, Martin, Wass, Mark N., Reddin, Ian, Voges, Yvonne, Rothweiler, Florian, Hehlgans, Stephanie, Cinatl, Jaroslav, Mernberger, Marco, Nist, Andrea, Stiewe, Thorsten, and others. (2020) YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting. Cancers, 12 (5). E-ISSN 2072-6694. (doi:10.3390/cancers12051080) (KAR id:81107)

PDF Publisher pdf
Language: English


Creative Commons Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.
Download (982kB) Preview
[img]
Preview
Official URL
https://doi.org/10.3390/cancers12051080

Abstract

Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) levels, decreased SLC35F2 (mediates YM155 uptake) levels, decreased survivin levels, and TP53 mutations indicate YM155 resistance. Here, the investigation of 10 additional YM155-adapted UKF-NB-3 sublines only confirmed the roles of ABCB1 and SLC35F2. However, cellular ABCB1 and SLC35F2 levels did not indicate YM155 sensitivity in YM155-naïve cells, as indicated by drug response data derived from the Cancer Therapeutics Response Portal (CTRP) and the Genomics of Drug Sensitivity in Cancer (GDSC) databases. Moreover, the resistant sublines were characterized by a remarkable heterogeneity. Only seven sublines developed on-target resistance as indicated by resistance to RNAi-mediated survivin depletion. The sublines also varied in their response to other anti-cancer drugs. In conclusion, cancer cell populations of limited intrinsic heterogeneity can develop various resistance phenotypes in response to treatment. Therefore, individualized therapies will require monitoring of cancer cell evolution in response to treatment. Moreover, biomarkers can indicate resistance formation in the acquired resistance setting, even when they are not predictive in the intrinsic resistance setting.

Item Type: Article
DOI/Identification number: 10.3390/cancers12051080
Uncontrolled keywords: acquired drug resistance; biomarkers; therapy monitoring; neuroblastoma; BIRC5; survivin; intrinsic drug resistance
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Martin Michaelis
Date Deposited: 04 May 2020 10:51 UTC
Last Modified: 05 May 2020 08:08 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/81107 (The current URI for this page, for reference purposes)
Michaelis, Martin: https://orcid.org/0000-0002-5710-5888
Wass, Mark N.: https://orcid.org/0000-0001-5428-6479
  • Depositors only (login required):

Downloads

Downloads per month over past year